Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabizabulin in High-Risk COVID-19
NCT04388826Phase 2Completed
- Sponsor
- Veru Inc.
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Veru-111 18 mg with Placebo (2 arms). Primary endpoint: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. Started Jun 2020; status: completed.
02
Drugs
sabizabulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04388826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388826.